Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Official Title

A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)

Brief Summary

      The primary objectives of this study are to investigate the efficacy and safety of topical
      steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of
      toxic epidermal necrolysis (TEN).

Detailed Description

      The experimental focus of this trial is thus to evaluate the safety and clinical outcomes of
      topical steroid (clobetasol 0.05% ointment) for treatment of the cutaneous manifestations of
      toxic epidermal necrolysis (TEN).

      The design of the study is a randomized, placebo-controlled, double-blind split-body Phase II
      clinical trial in which clobetasol 0.05% or placebo ointment will be topically applied to
      opposite arms for a period of fourteen days. The primary endpoints of the study are to
      determine the time to cessation of skin detachment in both groups as well as the safety of
      topical clobetasol to treat the cutaneous manifestations of TEN. Secondary outcome measures
      will evaluate efficacy by comparing the time to re-epithelialization and the percentage of
      affected skin between the clobetasol and placebo arms at various time points.

      An additional aim of the study is to characterize the genes expressed during the TEN disease
      state and any changes in gene expression following treatment with topical steroids,
      particularly those genes involved in the regulation of programmed cell death (apoptosis).
      This will be accomplished though molecular analysis of skin biopsy specimens obtained after
      treatment with clobetasol and placebo ointments. The specific hypothesis being tested is that
      two weeks of topical clobetasol will promote epidermal keratinocyte survival through
      suppression of TNF signaling, decreased granulysin expression and inhibition of other
      pro-apoptotic pathways resulting in shorter disease duration and decreased time to

      IRB number: 642415-5

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Safety (numeric cellulitis score)

Secondary Outcome

 Time to 90% re-epithelialization


Toxic Epidermal Necrolysis


Clobetasol 0.05% ointment

Study Arms / Comparison Groups

 Clobetasol 0.05% ointment
Description:  All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2016

Completion Date

February 6, 2019

Primary Completion Date

February 6, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Characteristic histological findings on diagnostic biopsy

          -  Clinical diagnosis verified by two independent physicians

          -  Greater than 10% affected body surface area (BSA)

          -  Ability to start treatment within seven days or less from the onset of erosions

          -  Actively worsening disease (enlarging area of involvement or new erosions occurring
             over the last 24 hours)

          -  Patient Body Surface Area (BSA) > 1.0 m2

          -  Reproductive age female patients must have a negative pregnancy test prior to

        Exclusion Criteria:

          -  Patients will be excluded if they are < 7 or > 85 years of age.

          -  Patients who have documented:

               -  Uncontrolled infection (e.g. documented bacteremia)

               -  Malignancy

               -  Known prior immunodeficiency

               -  Pregnancy

               -  Concurrent use of systemic corticosteroids in the burn center greater than or
                  equal to 0.5 mg/kg/day of prednisone or equivalent dose of similar medication.

               -  Greater than 70% eroded skin

               -  SCORETEN score >3 on hospital admission

          -  Patients will also be excluded if they have: active hepatitis and/or an ALT or AST
             greater than four times the normal limits, or renal insufficiency with an estimated
             GFR<50 mL/min/1.73m2.




7 Years - 85 Years

Accepts Healthy Volunteers



Emanual Maverakis, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

University of California, Davis

Study Sponsor

Emanual Maverakis, MD, Principal Investigator, University of California, Davis

Verification Date

August 2019